Contraindications
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
Diclazuril oral suspension was given to lambs as a single dose up to 60 times the therapeutic dose. No adverse clinical effects were reported. No adverse effects were noted either at 5 times the therapeutic dose administered four consecutive times with a 7-day interval. In calves, c.
Adverse events
Sheep (lambs) and Cattle (calves):
Very rare (<1 animal / 10,000 animals treated,including isolated reports): | Digestive tract disorder (e.g. Diarrhoea1,2) Lethargy, Recumbency Agitation Neurological signs (e.g. Paresis) |
1 with possible presence of blood
2 Some treated animals may show signs of clinical disease (diarrhoea) even though oocyst excretion is reduced to a very low level.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Special warnings
Avoid under-dosing, which may be due to underestimation of body weight, misadministration of the veterinary medicinal product or lack of calibration of the dosing device (if any).
Coccidiosis is an indicator of insufficient hygiene in the flock/pen. It is recommended to treat all lambs of the flock and all calves in a pen. This will contribute to reduce the infection pressure and assure a better epidemiological control of the coccidiosis infection.
The preferred timing of treatment is directed by the known epidemiology of Eimeria spp and if there is no recent and confirmed history of clinical coccidiosis, the presence of coccidia in the flock or herd should be confirmed by faecal sampling prior to treatment.
In certain cases, only a transient reduction of oocyst shedding may be achieved. Suspected clinical cases of resistance to anticoccidials should be further investigated and where evidence strongly suggest resistance to a particular antiprotozoal, an anticoccidial belonging to another pharmacological class and having a different mode of action should be used.
Frequent and repeated use of antiprotozoals may lead to the development of resistance in the target parasite.
Special precautions for use
Special precautions for safe use in the target species:
Lambs
On rare occasions, in highly susceptible lambs e.g. where they have been housed for long periods of time before being turned out onto heavily contaminated pasture, a severe scour has been seen shortly after dosing. In such cases, fluid therapy is essential.
Calves
Clinical coccidiosis generally occurs late in the parasite’s life cycle after most of the damage to the calf’s intestine has already been done. This severely damaged intestine can easily be infected by secondary bacteria and/or other agents. In cases of acute clinical coccidiosis treated with the veterinary medicinal product, fluid therapy is essential. Symptoms of clinical disease may remain obvious in some calves treated with the veterinary medicinal product, even though oocyst excretion is reduced to a very low level, and overall prevalence of diarrhoea is decreased.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
Use during pregnancy, lactation or lay
Not applicable.
Interaction with other medicinal products and other forms of interaction
None known.
Environmental properties
Diclazuril has been shown to be very persistent in soil.
Withdrawal period(s)
Meat and offal:
Sheep (lambs): zero days
Cattle (calves): zero days